The US Department of Health and Human Services (HHS) and the Department of Defense (DOD) have entered an agreement with Regeneron Pharmaceuticals to procure 1.4 million additional doses of the company’s antibody cocktail, REGEN-COV.

REGEN-COV is a combination of the two monoclonal antibodies casirivimab and imdevimab that can hinder SARS-CoV-2 infectivity.

As per the latest deal, Regeneron will deliver an additional 1.4 million doses of 1,200mg REGEN-COV to the US Government by 31 January next year for $2,100 per dose.

This takes the number of doses of REGEN-COV acquired by the US government to a total of approximately three million.

The company signed two similar deals with the US government in July last year and January.

Regeneron plans to commence delivery of the additional doses to the US government this month, with a huge majority of REGEN-COV to be supplied in the fourth quarter of this year.

In November last year, the US Food and Drug Administration (FDA) granted Emergency Use Authorisation (EUA) to the antibody cocktail for treating patients with mild to moderate Covid-19.

Indicated to treat certain adults as well as paediatric patients aged 12 years or above, the therapeutic can also be used in some post-exposure prophylaxis settings.

Last month, the FDA expanded the EUA for REGEN-COV to prevent Covid-19.

Furthermore, the REGEN-COV development programme yielded positive Phase III trial data across the range of Covid-19 infection, from prevention to hospitalisation.

Regeneron Pharmaceuticals president and CEO Leonard Schleifer said: “More than a year and a half into this pandemic, too many people are still being hospitalised and dying due to Covid-19.

“While vaccination remains the first line of defence to decrease the burden of Covid-19, REGEN-COV is a key tool that reduces the risk of hospitalisation or death by 70% in high-risk individuals when given early in the course of the infection.”

Regeneron is partnering with Roche to boost the international supply of REGEN-COV while Roche is handling the development and supply of the therapy outside the US.

As per the agreement signed by Roche and Regeneron in August last year, the former will be responsible for producing nearly one-third of the doses to fulfil the latest deal with the US Government.